These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 18759700)

  • 1. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME
    Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
    Taplin ME; Balk SP
    J Cell Biochem; 2004 Feb; 91(3):483-90. PubMed ID: 14755679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Naito S
    Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
    Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
    Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
    Wang G; Sadar MD
    J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Castration-resistant prostate cancer: locking up the molecular escape routes.
    Attar RM; Takimoto CH; Gottardis MM
    Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial androgen receptor targeted therapy for prostate cancer.
    Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
    Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel concepts in androgen receptor blockade.
    Hsieh AC; Ryan CJ
    Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
    Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP
    Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.
    Locke JA; Guns ES; Lehman ML; Ettinger S; Zoubeidi A; Lubik A; Margiotti K; Fazli L; Adomat H; Wasan KM; Gleave ME; Nelson CC
    Prostate; 2010 Feb; 70(3):239-51. PubMed ID: 19790237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts.
    Eder IE; Haag P; Bartsch G; Klocker H
    Future Oncol; 2005 Feb; 1(1):93-101. PubMed ID: 16555979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer.
    Griffiths K; Morton MS; Nicholson RI
    Eur Urol; 1997; 32 Suppl 3():24-40. PubMed ID: 9267783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.